Last reviewed · How we verify
Lurbinectedin alone
At a glance
| Generic name | Lurbinectedin alone |
|---|---|
| Sponsor | PharmaMar |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) (PHASE3)
- Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) (PHASE3)
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC (PHASE2)
- Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) (PHASE3)
- Patients With High-grade Pancreatic Neuroendocrine Tumors (PHASE2)
- Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors (PHASE1)
- Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors (PHASE1)
- Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |